The molecular characterization of bioactive molecules, for example, small molecules targeting G-protein-coupled receptors, is evolving in complexity, impacting the meaning of terms like "agonist", "antagonist", and "selective", which, in the absence of detailed definitions and scientific consensus, can be sources of confusion in the literature. We discuss this issue and offer straightforward solutions to it.
The Need to Improve Reporting of the Pharmacological Action of New Molecules
Marcello Leopoldo
2022-01-01
Abstract
The molecular characterization of bioactive molecules, for example, small molecules targeting G-protein-coupled receptors, is evolving in complexity, impacting the meaning of terms like "agonist", "antagonist", and "selective", which, in the absence of detailed definitions and scientific consensus, can be sources of confusion in the literature. We discuss this issue and offer straightforward solutions to it.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
